Fig. 2: BRD9 degrader treatment leads to inhibition of AML cell line proliferation. | Blood Cancer Journal

Fig. 2: BRD9 degrader treatment leads to inhibition of AML cell line proliferation.

From: BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Fig. 2

A–E Proliferation assays: AML cell lines treated with QA-68 or dBRD9-A. 6-day assay. Proliferation studies shown are representative of independent studies performed at least twice for which similar results were observed. F Effects of QA-68 (upper panel) and dBRD9-A (lower panel) on BRD9 expression in QA-68-sensitive and –insensitive AML cell lines. 24-hour assay. G Effects of QA-68 on SKM-1 cell differentiation. 4-day assay. H Effects of QA-68 on SKM-1 cell cycle progression. 6-day assay.

Back to article page